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Fibroblasts as therapeutic targets in rheumatoid
arthritis and cancer
Maria Juarez, Andrew Filer, Christopher D. Buckley
Rheumatology Research Group, IBR School of Immunity and Infection, University of Birmingham, United Kingdom
Summary
Rheumatoid arthritis (RA) is a common chronic inflammat-
ory disease that causes progressive synovial inflammation
resulting in irreversible joint destruction, chronic disability
and premature mortality [1, 2]. Although it is recognised
that in RA, inflammation and its persistence result from
complex interactions between haematopoietic and stromal
cells [3–5], research into the pathogenesis of the disease
has traditionally concentrated on cells and cytokines of the
immune system, neglecting the role of stromal cells. As
a consequence, new biologic treatments have been deve-
loped, which have led to a step-change in the management
of the disease [6]. Nevertheless, these treatments do not re-
verse tissue damage or lead to disease cure and are not ef-
fective for all patients. Furthermore, at best they induce a
significant clinical response (ACR70) in less than 60% of
patients, most of whom will relapse on treatment withdraw-
al, suggesting that additional therapeutic targets, respons-
ible for complete resolution of inflammation, remain to be
discovered [7]. An increasing body of evidence implicates
RA synovial fibroblasts in driving the persistent, destruct-
ive characteristics of the disease. In this paper, we discuss
the evidence implicating synovial fibroblasts in the patho-
genesis of RA and explore their role as therapeutic targets.
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Pathogenesis of RA
RA is an autoimmune disease, characterised by the devel-
opment of innate and adaptive immune responses and, in
a high percentage of patients, the presence of autoantibod-
ies (rheumatoid factor and anti-cyclic citrullinated peptide
antibodies) which may be detected in blood many years
before disease onset and whose pathogenic role remains
unclear [6]. Additionally, genetic factors such as most not-
ably the presence of the shared epitope (a specific group
of HLA-DR4 alleles) and single nucleotide polymorphisms
in the PTPN22 gene are known to play a part in disease
susceptibility and severity [8]. A number of environmental
factors have also been described. The association of
smoking with disease development in individuals who
carry the shared epitope and worse disease outcome is
well established [9]. Local factors such as hypoxia, which
is thought to be important in immune signalling and an-
giogenesis, are also relevant. However, a unified theory on
how these factors interact together is still elusive (for a re-
view on this topic see reference [10]).
At a local joint level, RA is characterised by a radical
change of the two compartments of the synovium. The lin-
ing layer of the tissue situated adjacent to the synovial fluid
compartment undergoes dramatic hyperplasia, sometimes
reaching 10–15 cells in depth with expansion of both mac-
rophage and fibroblast populations. At the articular borders
the thickened synovial lining layer may become a mass of
“pannus” tissue (rich in fibroblasts and osteoclasts) that in-
vades the adjacent articular cartilage and subchondral bone.
The sublining layer also undergoes expansion, with infilt-
rates of inflammatory cells including macrophages, mast
cells, T cells, B cells and plasma and dendritic cells. T and
B lineage cells may remain in diffuse infiltrates, or may co-
alesce into aggregates of cells varying from simple perivas-
cular “cuffs” a few cells in diameter to structures resem-
bling B-cell follicles in up to 20% of samples [11]. This
increased activity is supported by further extracellular mat-
rix (ECM) production and neoangiogenesis, although the
inflamed synovium remains in a state of relative hypoxia
[12].
The interactions between these different cell types are com-
plex and mediated by numerous cytokine networks. The
Figure 1
Representation of the different cell types in the rheumatoid
synovium.
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description of the relative contribution of each of these cell
types to disease pathogenesis is beyond the remit of this pa-
per but a schematic representation of the synovium’s cellu-
larity in RA has been depicted in figure 1.
Synovial fibroblasts in the
pathogenesis of RA
Over the last decade, researchers have demonstrated that in
addition to their well-known structural role in “landscap-
ing” the microenvironment, synovial fibroblasts are implic-
ated in the pathogenesis of RA at two fundamental levels.
Fibroblasts as mediators of persistent inflammation
Firstly, activated RA synovial fibroblasts play crucial roles
in determining the site at which inflammation occurs, and
in the subsequent maintenance of persistent inflammation
in the joint microenvironment, as reflected in hyperplasia
of resident stromal cells and the organisation of T and B
lymphocyte infiltration discussed above [11]. Much work
has been devoted to the description of this microenviron-
ment and of the complex haematopoietic-stromal cell inter-
actions that determine its stability [3–5]. We have proposed
that the maintenance of the persistent leukocyte infiltrate
results from a distorted homeostatic balance between leuk-
ocyte recruitment, proliferation, emigration and death [3],
and that synovial fibroblasts are key determinants of this
imbalance. In the rheumatoid synovium, different subpop-
ulations of stromal cells exist. Stromal cells of the RA
synovium differ from those of the normal synovium. Ad-
ditionally synovial fibroblasts from the lining layer differ
in biological and morphological characteristics to those of
the sublining layer. The so-called activated synovial fibro-
blasts found in RA tissue (RASFs) are the key stabilisers
of the abnormal synovial microenvironment. In a series of
experiments, our group and others have demonstrated that
activated RASFs produce inflammatory chemokines (e.g.,
Figure 2
Fibroblasts orchestrate chronic inflammation in RA. The
maintenance of persistent leukocyte infiltrates results from a
distorted homeostatic balance between leukocyte recruitment,
proliferation, emigration and death. Activated RASFs produce
inflammatory chemokines (IL-8, CXCL5, CXCL1) implicated in
leukocyte recruitment to diseased synovium, survival factors (type I
interferon, IL-15, BAFF) and constitutive chemokines (e.g. CXCL12,
CCL21). The net result is the chronic accumulation, survival and
retention of leukocytes at sites of disease.
IL-8, CCL5, CXCL1) [13, 14] that actively recruit leuk-
ocytes such as neutrophils and B and T lymphocytes to
the diseased synovial tissue. By contrast RASFs also inap-
propriately secrete so-called constitutive chemokines (e.g.,
CXCL12, CXCL13, CCL21) that are normally restricted
to lymphoid tissues in order to coordinate the recircula-
tion of lymphocytes [3, 15–18]. In this way, infiltrating
leukocytes are prevented from leaving the synovial tissue.
RASFs also produce survival factors (e.g., type I interfer-
on, IL-15, BAFF) that prevent leukocyte subpopulations
from dying by apoptosis as would normally occur during
the resolution phase of an inflammatory response [19–21].
Thus fibroblast activation results in the accumulation, sur-
vival and retention of leukocytes at sites of disease, mim-
icking the microenvironment seen in lymphoid tissues, and
thereby preventing the resolution of chronic inflammation
(fig. 2).
Fibroblasts as mediators of joint destruction
Secondly, RASFs are key mediators of cartilage and bone
destruction. They act directly on cartilage via secretion of
matrix metalloproteinases (MMPs), cathepsins and inflam-
matory cytokines [22, 23], and indirectly on bone via reg-
ulation of monocyte to osteoclast differentiation [24]. In
the early RA joint, activated synovial fibroblasts attach to
and overgrow the cartilage surface, then invade and des-
troy cartilage and induce bone resorption (fig. 3). Active
degradation of cartilage in vivo has been elegantly demon-
strated in the SCID mouse model of arthritis, in which in
vitro cultured RASFs (but not normal or osteoarthritis syn-
ovial fibroblasts) attach to and invade co-implanted healthy
Figure 3
Fibroblast contribute to joint damage. Pannus tissue consists of
activated RASFs that attach to and damage cartilage through
production of MMPs and cathepsins. In addition, fibroblasts secrete
RANKL, which promotes osteoclast differentiation and activation,
leading to bone erosions. Furthermore production of DKK-1 inhibits
Wnt signaling pathways that normally promote anabolic osteoblast
activity, preventing repair of bone erosions. Abbreviations: MMPs:
matrix metalloprotenaises; RANKL: receptor activator of nuclear
factor k B ligand; DKK-1: dickkopf-1.
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human cartilage in the absence of cells of the immune sys-
tem, indicating that this invasive phenotype is both stable
and disease specific [25]. Furthermore, RASFs maintain
this destructive phenotype even after multiple in vitro pas-
sages, and their in vitro invasiveness correlates with clinic-
al rates of bone erosion in individual patients [26].
Initial and persistent activation of RASFs
It is therefore clear that activated RASFs are not passive
players in immune responses but key effectors in the patho-
genesis of RA. One of the questions arising from these ob-
servations is how these cells become activated and how this
activated phenotype persists.
It has been proposed that activation arises from molecular
cross-talk between RASFs and other cells of the synovial
microenvironment early in disease. Pro-inflammatory cy-
tokines of the initial rheumatoid microenvironment such as
TNFα and IL-1 play a key role in the activation of RASFs
[23]. Once activated, RASFs produce TNFα, IL-1 and IL-6
that are involved in sustaining regulatory feedback loops
and induce production of MMPs, cathepsins, aggrecanases
and their inhibitors [6]. However, independently of the fact
that pro-inflammatory cytokines induce fibroblast activa-
tion, the fact that not all fibroblasts in a joint become ac-
tivated suggests that there must be other mechanisms in
play (intrinsic to these cells) that make them “permissive”
to such activation. Indeed, it has conclusively been shown
that the persistence of the activated RASFs phenotype is in-
dependent of the pro-inflammatory cytokines that initiated
the process [25] This may also explain the clinical observa-
tion that cessation of anti cytokine therapy (e.g., anti TNF
therapy) in the context of clinical RA leads to disease flare
[10].
Mechanisms of activation
So, what could these intrinsic mechanisms be? Cellular
DNA and the epigenetic machinery that regulates its ex-
pression are the most plausible candidates to explain
unique cellular characteristics.
Several lines of evidence indicate that responses to pro-
inflammatory stimuli result from persistent changes in the
transcription levels of disease relevant genes. RASFs show
upregulated expression of proto-oncogenes (c-myc) [27],
Figure 4
Schematic representation of epigenetics. Epigenetic changes mark
the genome at specific sites acting as switches that determine
whether a particular gene is transcribed (switch “on”) or not (switch
“off”). In the figure an activating mark results in normal transcription
of a tumour suppressor gene and maintenance of normal cell
phenotype whilst a repressing mark in the same gene results in
lack of transcription and malignant transformation of that cell line.
Abbreviations: P: promoter; E: exon.
adhesion molecules (VLA-3, VLA-4, VLA-5) [28] and
MMPs (MMP13, MT-MMP) [29, 30] whilst displaying low
expression of tumor suppressor genes such as PTEN and
p53 [31]. These persistent changes in gene transcription
are ultimately responsible for the aggressive behaviour of
RASFs. Differential gene expression patterns are not only
apparent in disease but also in health and indeed fibroblasts
from different anatomical regions have been shown to dis-
play characteristic transcriptional profiles that are main-
tained in vitro [32]. The HOX genes encode the important
transcription factors that confer such region-specific iden-
tity to tissues [32–34]. But how is this differential gene ex-
pression pattern obtained and regulated to provide persist-
ent changes in phenotype? The field of epigenetics explains
such regulation, and is increasingly implicated as the de-
terminant of the RASFs phenotype.
Epigenetic changes are hereditable changes in gene expres-
sion that do not result from alteration of the underlying
DNA sequence [35]. Figure 4 provides a schematic repres-
entation of epigenetic mechanisms. The most studied epi-
genetic modifications to date include non-coding RNA spe-
cies, DNA methylation and histone modifications. These
modifications can be thought of as chemical “switches”
that regulate gene expression determining whether a par-
ticular gene is expressed (“on”) or not (“off”). In healthy
fibroblasts, expression of a non-coding RNA (termed
HOTAIR) residing in the HOXC locus results in silencing
of genes in the HOXD locus, explaining epigenetic control
of HOX gene expression in health [36]. In RA, RASFs dis-
play global genomic DNA hypomethylation (an epigenetic
change associated with up-regulation of gene expression)
that causes up-regulation of disease relevant genes (growth
factors, adhesion molecules and MMPs) [37]. Most not-
ably, treatment of normal synovial fibroblasts with the
DNA methylation inhibitor 5-aza-2′deoxycytidine (decita-
bidine) resulted in their transformation into cells resem-
bling activated RASFs [37]. Although this evidence lends
support to epigenetic changes as determinants of the
RASFs persistent phenotype, further research in this area is
needed to unequivocally demonstrate a significant role in
the pathogenesis of disease.
Perhaps more noteworthy is that the epigenetic hypothesis
may not only provide a mechanistic explanation for this
phenotype but a tool to modify it. Most epigenetic modi-
fications are reversible processes catalysed by specific en-
zymes and cofactors that allow cells to change their gene
expression patterns in response to various stimuli. The en-
zymes and molecular complexes involved in these pro-
cesses represent very attractive targets for future therapies.
As a result, much interest is currently being devoted to this
area.
Cancer associated fibroblasts
The importance of the stromal microenvironment in dis-
ease has been recognised in the cancer field for years. It is
now widely accepted that cancer develops as a result of ge-
netic and epigenetic alterations in clonal cells, but that the
growth, survival and metastasis of these cells are regulated
by stromal-cancer cell interactions [38]. Studies in human
lung, breast, colon and prostate cancer have unequivocally
demonstrated a key role for stromal cells (so-called cancer
Review article: Medical intelligence Swiss Med Wkly. 2012;142:w13529
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associated fibroblasts (CAFs)) in initiation and progression
of disease [38]. The term “cancer stroma” has been coined
to refer to macroscopic and functional differences between
this and the corresponding normal tissue stroma. Cancer
stroma is characterized by a modified ECM composition,
increased microvessel density, inflammatory cells and ac-
tivated fibroblasts [39]. Autocrine and paracrine mechan-
isms resulting in secretion of cytokines, chemokines and
growth factors by the stromal microenvironment have been
implicated in activation and transformation of fibroblasts
into CAFs [40]. Platelet derived growth factor (PDGF) [41]
and transforming growth factor beta (TFGβ) are the most
important factors in this process. They regulate disease rel-
evant gene expression (fibronectin, PAI-1 and cyclin de-
pendent kinase inhibitors) [42, 43] through stimulation of
specific signaling cascades like serine/threonine kinase re-
ceptors and the STAT (Signal Transduction and Activation
of Transcription) family of signaling pathway regulators.
Confirmation of the importance of CAFs comes from in
vivo studies: co-implantation of pre-malignant prostate epi-
thelial cells with prostate tumour CAFs, but not normal
prostate fibroblasts, leads to malignant transformation and
proliferation of epithelial cells [44]. In breast cancer, over-
expression of TGFβ in mouse fibroblasts induces initiation
of breast cancer within normal human epithelium [45].
Targeting CAFs
This compelling evidence demonstrates that tumour-host
cross talk at the level of the resident fibroblast cell determ-
ines the behaviour of malignant cells. As a result, ther-
apies targeting the tumour stroma are being developed and
a number of strategies have been proposed:
1. Targeting signals responsible for activation of
fibroblasts: the key role of PDGF and TGFβ signaling
pathways has resulted in the development of inhibitors
against these molecules. Imatinib (Glivec) inhibits the
PDGF-receptor tyrosine kinase and is used for the
treatment of chronic myeloid leukaemia and other
types of cancer [46]. TGFβ inhibitors are currently in
development (e.g., lerdelimumab, metelimumab) [47].
2. Targeting fibroblast specific molecules that initiate and
promote tumour growth: an example of this approach
is the use a humanised monoclonal antibody
(sibrotuzumab) against the fibroblast activation protein
(FAP) [48]. FAP is a membrane bound glycoprotein
with serine protease activity. It is highly expressed in
the tumour stroma and has been shown to enhance
tumour growth in vivo [49]. Efficacy has been shown
in phase I studies in colorectal cancer. [50]
3. Eliminating activated CAF subpopulations: efforts are
being made to determine the differential transcriptional
profile of normal fibroblasts compared to CAFs in a
variety of malignancies in order to identify unique
transcriptional signatures. This will then be further
investigated in order to develop new therapies aimed
towards elimination of CAFs.
4. Epigenetic therapies. Although still in its early days,
research has shown that epigenetic modifications
determine the phenotype of cancer and tumour stroma
cells promoting their invasiveness and survival. CAFs
in human gastric carcinomas exhibit global DNA
hypomethylation [51]. More broadly, cancerous
epithelial cells are characterized on the one hand by
global DNA hypomethylation that promotes
chromosomal instability and activates proto-
oncogenes, and on the other by regional promoter
hypermethylation of specific genes that results in
down-regulation of tumour suppressor genes [52]. The
understanding of the molecular basis of these
epigenetic modifications has led to the development of
epigenetic therapies. The DNA methylation inhibitor
5-aza-2′deoxycytidine is currently used for the
treatment of myelodysplastic syndromes (MDS),
acting by reversing pathological hypermethylation
(and hence increasing expression) of the tumour
suppressor gene CDKN2B in affected cells [52].
As the understanding of global epigenetic mechanisms in
cancer advances, a combinatorial approach using different
epigenetic approaches along with standard chemotherapy
holds significant promise for effective future treatment. For
example, it has been shown that treatment of MDS with
5-aza-2′deoxycytidine is limited by a short duration of re-
sponse that is improved upon use of combination chemo-
therapy [53].
Towards targeting synovial fibroblasts in the treatment
of rheumatoid arthritis
Obvious parallels can be drawn between CAFs and RASFs,
and indeed current RA research is focusing increasingly
upon targeting stromal cells therapeutically.
Non- Fibroblast specific mechanisms
1. Cytokine blockade. Existing strategies in RA have
indirectly targeted stromal cells either by targeting
cytokines which impact upon fibroblasts such as anti-
TNF therapies (infliximab, etanercept, adalimumab) or
by blocking their significant products (anti-IL-6
receptor, tocilizumab) therapies respectively. These
therapies share the shortcomings of existing biologics,
inhibiting key pleiotropic proinflammatory cytokines
with widespread generic roles, leading on the one hand
to significant adverse events despite submaximal
efficacy, while on the other hand failing to address
persistence of disease.
2. Cell signalling pathways. Cellular MAPKinase and NF-
κB signalling pathways in particular are heavily
implicated in the pro-inflammatory and cartilage
damaging activities of synovial fibroblasts. However,
the consequences of inhibiting such generic pathways
in terms of off-target effects has been likened to
opening Pandora’s box [54]. As described in the field
of cancer medicine, the approach of targeting more
specific upstream activators of pathologically altered
fibroblasts via inhibitors of tyrosine kinase family
members may lead to fewer off-target effects; imatinib
inhibits a narrow family of tyrosine kinases including
the PDGF receptor, c-fms and c-kit. It shows promise
as a therapy in RA that has been shown to modulate
synovial fibroblast proliferation rates [55, 56].
Review article: Medical intelligence Swiss Med Wkly. 2012;142:w13529
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Fibroblast specific mechanisms
1. Novel fibroblast markers. Historically, the study of
fibroblasts has been hampered by a lack of specific
cell surface markers. As a result, they have
traditionally been identified by their spindle-shaped
morphology, elaboration of ECM and lack of markers
associated with endothelial, epithelial or
haematopoietic cells. This situation is now rapidly
changing; an early discovery in this field revealed that
the lining layer of synovial fibroblasts is associated
with specific expression of cadherin-11, an adhesion
molecule responsible for homotypic adhesion between
lining layer stromal cells which self organise in the
absence of a basement membrane [57]. Not only does
this marker co-localise with cells of the lining layer,
but in cadherin-11 knockout mice subjected to models
of inflammatory arthritis, damage to the joint cartilage
is ameliorated [58]. Although not a realistic
therapeutic target in isolation, this provided proof of
concept that deletion of a stromal sub-population
marker could impact on progression of animal models
of disease. Further synovial stromal markers have been
identified in the rheumatoid synovium with strong
overlap with CAF markers. These include FAP, and the
sub-lining marker CD248 (endosialin), with restricted
stromal expression, and important roles in cancer
progression, linkage of hypoxia to angiogenesis, and
stromal responses to inflammation [59–61]. Maia et al.
have shown that full knockouts and cytoplasmic tail
mutants of CD248 result in amelioration of murine
arthritis induced by anti-collagen antibodies, offering
potential as a therapeutic target [62]. Other specific
markers include PBEF (Visfatin), an adipokine with
expression closely linked to RA disease activity [63],
and FAP, which is expressed in the lining layer of the
pathological rheumatoid joint. Inhibitors exist which
specifically inhibit both molecules, though exploring
their use in arthritis is at an early stage [64, 65].
2. Epigenetic therapies. In vitro and in vivo studies of the
use of epigenetic therapies in arthritis have started to
emerge. Histone acetylation/decacetylation is an
epigenetic modification that has a critical role in
regulation of gene transcription by altering chromatin
structure. Jüngel and colleagues [66] treated RASFs
with the histone deacetylase inhibitor Trichostatin A
(TSA). Treatment resulted in inhibition of their
proliferation and sensitisation to tumour necrosis
factor related apoptosis-inducing ligand (TRAIL)
induced apoptosis. Subsequently, Nasu and colleagues
[67] conducted an elegant in vivo study to analyse the
effects of TSA treatment in the collagen antibody
induced arthritis (CAIA) mouse model. Mice were
given subcutaneous injections of TSA and histological
analysis showed amelioration of clinical arthritis in a
dose dependent manner. These studies provide proof
of concept that epigenetic therapies may become a
reality for the treatment of arthritis. Non-coding RNA
species such as microRNAs (miRs) are also becoming
rapidly recognised as relatively specific controllers of
aberrant gene expression [68]. MiR expression is itself
frequently under epigenetic control, highlighting a
central mechanism in cancer pathology. One such
example in arthritis is miR203. This molecule is under
the direct control of DNA methylation, and drives
expression of IL-6 and MMP production by synovial
fibroblasts. Not only are levels of miR203 raised in
longstanding RA compared to osteoarthritis and
normal synovial fibroblasts, but expression in the
earliest phases of RA when disease is not fully
differentiated occurs at an intermediate level,
suggesting that the epigenetic control of synovial
fibroblast behaviour remains plastic in the earliest
phases of disease [69].
At present, experimental approaches to epigenetic modi-
fications have used broad specificity drugs such as TSA
and 5-aza-2′deoxycytidine. However, as discussed above,
pathological epigenetic changes in carcinoma cells involve
complex combinations of gene activation and repression.
These therapies do not therefore represent a final goal for
rational drug design. The potential for targeted therapy is
made possible by the complexes that effectively “read” and
“write” the epigenetic code via DNA methylation and a
multitude of histone modifications. These complexes, such
as the acetyl-lysine reading bromodomains [70] demon-
strate high specificity for certain modifications and groups
of genes. Engineering of specific antagonists to active sites
in these complexes can radically alter disease, as in the
case of a malignancy inducing translocation treated by Fil-
ippakopoulos et al. who generated a specific cell permeable
competitive inhibitor that prevented binding of the BET
bromodomain member BRD4, forcing differentiation of a
previously incurable cancer [71].
Conclusion
Synovial fibroblasts are key effectors in the pathogenesis
of RA. Aspects of the mechanisms involved in the trig-
gering of their abnormal phenotype have begun to be de-
ciphered. Drugs aimed at these cells either via targeting of
markers for specific pathologically important subpopula-
tions or modulating epigenetic programming of fibroblasts
may be added to the therapeutic arsenal in RA in the near
future. Just as in the field of cancer, combinations of epi-
genetic and conventional antirheumatic therapies may both
improve efficacy and modify disease persistence.
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Figures (large format)
Figure 1
Representation of the different cell types in the rheumatoid synovium.
Figure 2
Fibroblasts orchestrate chronic inflammation in RA. The maintenance of persistent leukocyte infiltrates results from a distorted homeostatic
balance between leukocyte recruitment, proliferation, emigration and death. Activated RASFs produce inflammatory chemokines (IL-8, CXCL5,
CXCL1) implicated in leukocyte recruitment to diseased synovium, survival factors (type I interferon, IL-15, BAFF) and constitutive chemokines
(e.g. CXCL12, CCL21). The net result is the chronic accumulation, survival and retention of leukocytes at sites of disease.
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Figure 3
Fibroblast contribute to joint damage. Pannus tissue consists of activated RASFs that attach to and damage cartilage through production of
MMPs and cathepsins. In addition, fibroblasts secrete RANKL, which promotes osteoclast differentiation and activation, leading to bone
erosions. Furthermore production of DKK-1 inhibits Wnt signaling pathways that normally promote anabolic osteoblast activity, preventing repair
of bone erosions. Abbreviations: MMPs: matrix metalloprotenaises; RANKL: receptor activator of nuclear factor k B ligand; DKK-1: dickkopf-1.
Figure 4
Schematic representation of epigenetics. Epigenetic changes mark the genome at specific sites acting as switches that determine whether a
particular gene is transcribed (switch “on”) or not (switch “off”). In the figure an activating mark results in normal transcription of a tumour
suppressor gene and maintenance of normal cell phenotype whilst a repressing mark in the same gene results in lack of transcription and
malignant transformation of that cell line. Abbreviations: P: promoter; E: exon.
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